Takeda reintegrates U.K. sales team; Philidor continues downsizing with layoffs;

@FiercePharma: Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Huge consumer med capacity coming online for Bayer in China as the economy tanks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: $GSK vaccines head Slaoui says the company's vax and pharma businesses need each other--aka, no break-up, please | Follow @CarlyHFierce

> Takeda, which had its sales team in the U.K. under management by Ashfield Healthcare, is moving the group back under the Takeda fold. Story

> Specialty pharmacy Philidor Rx Services has dismissed 264 employees in the Phoenix area as it continues to wind down after its failed relationship with Valeant Pharmaceuticals ($VRX). Story

> India's Piramal Enterprises is reportedly in talks to sell a 20% stake in is over-the-counter business. Report

> Esteban Plata has been named vice president of Western Europe and Canada for AbbVie ($ABBV), replacing Pascale Richetta who is stepping down at the end of the month. Report

Medical Device News

@FierceMedDev: FDA makes increasing use of 'real-world' device data a strategic priority. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Heartware shares plunge on bad new about device trial. Article | Follow @VarunSaxena2

@EmilyWFierce: NIH urged to 'break taboo' against using its power to bypass drug patents. FiercePharma article | Follow @EmilyWFierce

> JPM: St. Jude plagued by gap in its portfolio of pacemakers and implantable defibrillators. Story

> NIH commits $313M over four years to sequencing genomics of human disease. Article

> Devices grab $2.7B in VC again, but that may weaken in 2016. Editor's corner

Biotech News

@FierceBiotech: Johns Hopkins flags another possible successor to 'Special K' for depression. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Did I say the eteplirsen data was messy? More from the FDA (PDF) | Follow @JohnCFierce

@DamianFierce: $MRK is mad about Merck, KGaA, Darmstadt, Germany, Earth's rebrand. More (PDF) | Follow @DamianFierce

> FDA delays decision on Heron's twice-rejected nausea drug. Report

> Sarepta shares crash on a harsh FDA review of Duchenne's drug. Article

> Biotech rehearses its 'difficult' second album at #JPM16. Editor's corner

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.